STELLULAR BIO, INC.
Biotech · Private
Off-the-shelf allogeneic cell therapy derived from platelet and stem cell biology for Sjögren's syndrome-related dry eye
- Grants
- $5.4M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 18
- 4 granted · 14 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Assessment of Bioreactor-Derived Human Platelet Quality, Storage Profile, Safety, and Function | $729,375 | |
| Federal grant | Department of Health and Human Services · Phase I · Platelet Bioreactor for Treatment of Radiation-Induced Thrombocytopenia | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Assessment of Bioreactor-Derived Human Platelet Quality, Storage Profile, Safety, and Function | $729,375 | |
| Federal grant | Department of Health and Human Services · Phase I · Platelet Bioreactor for Treatment of Radiation-Induced Thrombocytopenia | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · PLT+ Characterization and IND-Enabling Studies | $2,022,100 | |
| Federal grant | Department of Health and Human Services · Phase II · PLT+ Characterization and IND-Enabling Studies | $952,100 | |
| Federal grant | Department of Health and Human Services · Phase II · Scale-up and Manufacturing of STLR-201, an off-the-shelf regenerative therapeutic for Sjogren's syndrome-related dry eye disease | $356,485 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2427 | WEKA BIOSCIENCES LLC | — | — |
| 2428 | SOLLUS THERAPEUTICS, INC. | — | — |
| 2429 | Advanced Vision Technologies, Inc. | — | — |
| 2430 | STELLULAR BIO, INC. | — | — |
| 2431 | SYNTHETIC VECTOR DESIGNS, LLC | — | — |
| 2432 | GLSYNTHESIS, INC. | — | — |
| 2433 | PRAXIS BIORESEARCH, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Megakaryocyte Derivatives For Treatment Of Dry Eye Diseasesapplication
- Compositions for Drug Delivery and Methods of Use Thereofapplication
- Compositions for Drug Delivery and Methods of Use Thereofapplication
- Compositions for Drug Delivery and Methods of Use Thereofgranted
- Compositions for Drug Delivery and Methods of Use Thereofgranted
- Compositions and Methods for Producing Megakaryocytesapplication
- Stacked Recirculating Bioreactorgranted
- Compositions and Methods for Producing Megakaryocytesgranted
- Recirculating Bioreactorapplication
- Methods And Production Of Novel Plateletsapplication
- Novel Anucleated Cells As A Source For Treatment Of Platelet Rich Plasma Dependent Disordersapplication
- Systems And Methods For Forming A Fluidic Systemapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.